Live price temporarily unavailable.
Black Diamond Therapeutics (BDTX) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | — | — | — | $0 | $70.0M |
| Operating income | −$8.90M | −$29.3M | −$69.6M | −$126.9M | −$92.8M | −$86.5M | −$78.8M | $12.5M |
| Operating margin | — | — | — | — | — | — | — | 17.9% |
| Net income | −$8.93M | −$35.3M | −$67.3M | −$125.6M | −$91.2M | −$82.4M | −$69.7M | $22.4M |
| Net margin | — | — | — | — | — | — | — | 32.0% |
| EPS (diluted) | −$4.42 | −$16.99 | −$2.05 | −$3.47 | −$2.52 | −$1.88 | −$1.27 | $0.39 |
| Balance sheet | ||||||||
| Cash and equivalents | $51.7M | $154.7M | $34.6M | $65.8M | $34.3M | $56.2M | $36.4M | $21.0M |
| Total assets | $51.8M | $158.3M | $329.7M | $247.7M | $156.3M | $158.6M | $122.6M | $143.0M |
| Total liabilities | $6.60M | $4.88M | $21.9M | $51.8M | $40.6M | $41.8M | $39.4M | $30.8M |
| Shareholders' equity | −$15.5M | −$47.2M | $307.8M | $195.9M | $115.7M | $116.7M | $83.3M | $112.2M |
| Cash flow | ||||||||
| Operating cash flow | −$8.45M | −$24.7M | −$52.1M | −$100.1M | −$85.1M | −$66.7M | −$62.3M | $29.6M |
| Capital expenditure | $76.0K | $21.0K | $142.0K | $2.71M | $192.0K | $33.0K | $0 | — |
| Free cash flow | −$8.53M | −$24.7M | −$52.3M | −$102.9M | −$85.3M | −$66.8M | −$62.3M | — |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $70.0M | $0 | $0 | — | $0 | $0 |
| Growth (year over year) | — | — | — | — | — | — | −100.0% | — |
| Operating income | −$18.1M | — | $54.5M | −$13.4M | −$11.0M | — | −$11.3M | −$12.1M |
| Operating margin | — | — | 77.9% | — | — | — | — | — |
| Net income | −$15.6M | — | $56.5M | −$10.6M | −$8.50M | — | −$9.04M | −$9.90M |
| Net margin | — | — | 80.8% | — | — | — | — | — |
| EPS (diluted) | −$0.28 | — | $0.98 | −$0.19 | −$0.15 | — | −$0.16 | −$0.17 |
| Balance sheet | ||||||||
| Cash and equivalents | $23.4M | $36.4M | $98.4M | $30.0M | $30.9M | $21.0M | $30.1M | $19.2M |
| Total assets | $137.9M | $122.6M | $176.2M | $166.4M | $157.7M | $143.0M | $132.9M | $125.0M |
| Total liabilities | $40.5M | $39.4M | $34.7M | $33.8M | $31.6M | $30.8M | $28.6M | $28.9M |
| Shareholders' equity | $97.4M | $83.3M | $141.5M | $132.6M | $126.2M | $112.2M | $104.3M | $96.1M |
| Cash flow | ||||||||
| Operating cash flow | −$11.3M | — | $53.4M | −$9.16M | −$7.85M | — | −$10.2M | −$7.97M |
From Black Diamond Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
No recent news mentioning Black Diamond Therapeutics in our feed yet.